Eli Lilly and Company, Novo Nordisk A/S, Thermo Fisher Scientific, AbbVie, and Pfizer are the five Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of companies that research, develop, manufacture and sell medications and therapies. Investors buy these equities to gain exposure to the healthcare sector’s growth, though their value can fluctuate significantly with drug trial outcomes, regulatory approvals and patent expirations. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.
Eli Lilly and Company (LLY)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
NYSE:LLY traded up $19.74 during midday trading on Friday, hitting $759.81. The stock had a trading volume of 2,883,252 shares, compared to its average volume of 3,794,217. The stock has a 50-day moving average of $774.56 and a 200 day moving average of $799.73. The company has a quick ratio of 1.06, a current ratio of 1.37 and a debt-to-equity ratio of 2.18. The company has a market capitalization of $720.10 billion, a price-to-earnings ratio of 61.82, a PEG ratio of 1.08 and a beta of 0.40. Eli Lilly and Company has a one year low of $677.09 and a one year high of $972.53.
Read Our Latest Research Report on LLY
Novo Nordisk A/S (NVO)
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.
NVO stock traded up $0.71 during midday trading on Friday, reaching $47.78. The stock had a trading volume of 26,110,554 shares, compared to its average volume of 10,671,057. The firm has a fifty day simple moving average of $69.64 and a two-hundred day simple moving average of $72.95. The stock has a market cap of $213.34 billion, a PE ratio of 14.14, a P/E/G ratio of 0.97 and a beta of 0.64. Novo Nordisk A/S has a 52-week low of $46.90 and a 52-week high of $139.74. The company has a debt-to-equity ratio of 0.70, a quick ratio of 0.56 and a current ratio of 0.74.
Read Our Latest Research Report on NVO
Thermo Fisher Scientific (TMO)
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Shares of NYSE TMO traded down $6.97 during trading on Friday, reaching $460.71. 1,758,000 shares of the company traded hands, compared to its average volume of 2,524,675. The firm's fifty day simple moving average is $419.50 and its 200 day simple moving average is $468.31. The stock has a market cap of $173.91 billion, a P/E ratio of 26.65, a PEG ratio of 2.55 and a beta of 0.77. Thermo Fisher Scientific has a 12-month low of $385.46 and a 12-month high of $627.88. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65.
Read Our Latest Research Report on TMO
AbbVie (ABBV)
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
Shares of NYSE ABBV traded up $6.93 during trading on Friday, reaching $195.95. 3,976,154 shares of the company traded hands, compared to its average volume of 6,847,337. The firm's fifty day simple moving average is $188.10 and its 200 day simple moving average is $190.04. The stock has a market cap of $346.12 billion, a P/E ratio of 83.38, a PEG ratio of 1.25 and a beta of 0.48. AbbVie has a 12-month low of $163.81 and a 12-month high of $218.66. The company has a current ratio of 0.76, a quick ratio of 0.64 and a debt-to-equity ratio of 44.14.
Read Our Latest Research Report on ABBV
Pfizer (PFE)
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Shares of NYSE PFE traded up $0.15 during trading on Friday, reaching $23.44. 32,654,443 shares of the company traded hands, compared to its average volume of 45,258,391. The company has a current ratio of 1.26, a quick ratio of 0.96 and a debt-to-equity ratio of 0.64. Pfizer has a 12-month low of $20.92 and a 12-month high of $31.32. The firm's fifty day simple moving average is $24.36 and its 200 day simple moving average is $24.60. The stock has a market cap of $133.24 billion, a P/E ratio of 16.98, a PEG ratio of 0.86 and a beta of 0.58.
Read Our Latest Research Report on PFE
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Eli Lilly and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.
While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
